Article
Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2018
Hammerlindl Heinz, Ravindran Menon Dinoop, Hammerlindl Sabrina, Emran Abdullah Al, Torrano Joachim, Sproesser Katrin, Thakkar Divya, Xiao Min, Atkinson Victoria G, Gabrielli Brian, Haass Nikolas K, Herlyn Meenhard, Krepler Clemens, Schaider Helmut
Abstract excerpt
Purpose: Identify and characterize novel combinations of sorafenib with anti-inflammatory painkillers to target difficult-to-treat RAS-mutant cancer.Experimental Design: The cytotoxicity of acetylsalicylic acid (aspirin) in combination with the multikinase inhibitor sorafenib (Nexavar) was assessed in RAS-mutant cell lines in vitro The underlying mechanism for the increased cytotoxicity was investigated using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.